Summary of ARS Pharmaceuticals Conference Call Company Overview - **Company**: ARS Pharmaceuticals (NasdaqGM:SPRY) - **Product**: Neffy, the first FDA-approved needle-free epinephrine nasal spray Key Goals for 2026 - **Access Expansion**: Aim to achieve around 90% coverage by summer 2026, focusing on securing larger payers for unrestricted access [5][6] - **Medicaid Coverage**: Anticipate onboarding several Medicaid states, with Florida expected to be next [6] - **Phase 2b Study on Urticaria**: Ongoing study with plans for interim analysis by summer 2026, which may be significant due to previous positive results [7][8] Commercial Strategy - **Get Neffy on Us Program**: Aims to alleviate physician burden from prior authorizations (PAs) by providing virtual prescription options [11][12] - **Patient and Caregiver Burden**: The program simplifies the process for patients, reducing wait times for prescriptions [16][18] Market Dynamics - **Epinephrine Market**: Approximately 50-60% of the market consists of refills due to expiration, with a significant portion of prescriptions being filled virtually [22][24] - **Neffy Uptake**: 75% of neffy users are switching from auto-injectors, while 25% are new patients who previously did not fill prescriptions [30][32] Coverage and Awareness - **Commercial Coverage**: 57% of covered lives have unrestricted access, with 93% overall coverage including those requiring PAs [43][44] - **Direct-to-Consumer (DTC) Campaign**: Increased consumer awareness from 20% to over 60%, with a focus on the benefits of neffy [47][48] Partnership Insights - **ALK Partnership**: Positive relationship with ALK-Abelló, with successful launches in Europe, particularly in Germany and the UK, where neffy has gained significant market share [55][56] Urticaria Study Insights - **Potential Market**: Neffy could serve as an effective treatment for urticaria flares, with a focus on low-dose administration to minimize side effects [64][66] - **Economic Argument**: Potential to reduce emergency room visits, making it appealing to insurance companies [65] Future Outlook - **Manufacturing Expansion**: Plans for a second manufacturing site in Europe and potential site in China to support market growth [78] - **Market Underappreciation**: The food allergy market and the value of the urticaria indication are seen as underrecognized opportunities [79][80] Conclusion - ARS Pharmaceuticals is strategically positioned to expand its market presence with neffy, focusing on access, awareness, and innovative treatment options for both food allergies and urticaria. The company is optimistic about its growth trajectory and the potential impact of its products on patient care.